BR112012008889A2 - compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes - Google Patents

compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes

Info

Publication number
BR112012008889A2
BR112012008889A2 BR112012008889A BR112012008889A BR112012008889A2 BR 112012008889 A2 BR112012008889 A2 BR 112012008889A2 BR 112012008889 A BR112012008889 A BR 112012008889A BR 112012008889 A BR112012008889 A BR 112012008889A BR 112012008889 A2 BR112012008889 A2 BR 112012008889A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical use
treat diabetes
spiropiperidine compounds
spiropiperidine
compounds
Prior art date
Application number
BR112012008889A
Other languages
English (en)
Inventor
Hamdouchi Chafiq
Pankaj Lineswala Jayana
Maiti Pranab
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012008889(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112012008889A2 publication Critical patent/BR112012008889A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Abstract

composto de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes. a presente invenção refere-se ao composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo bem como uma composição e método para tratar diabetes.
BR112012008889A 2009-10-15 2010-10-11 compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes BR112012008889A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11
PCT/US2010/052126 WO2011046851A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Publications (1)

Publication Number Publication Date
BR112012008889A2 true BR112012008889A2 (pt) 2019-09-24

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008889A BR112012008889A2 (pt) 2009-10-15 2010-10-11 compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes

Country Status (24)

Country Link
US (1) US8383642B2 (pt)
EP (1) EP2488500A1 (pt)
JP (1) JP2013508279A (pt)
KR (1) KR20120051777A (pt)
CN (1) CN102574807A (pt)
AR (1) AR078522A1 (pt)
AU (1) AU2010307094A1 (pt)
BR (1) BR112012008889A2 (pt)
CA (1) CA2777775A1 (pt)
CL (1) CL2012000921A1 (pt)
CO (1) CO6531458A2 (pt)
CR (1) CR20120177A (pt)
DO (1) DOP2012000105A (pt)
EA (1) EA201270560A1 (pt)
EC (1) ECSP12011799A (pt)
IL (1) IL218344A0 (pt)
MA (1) MA33662B1 (pt)
MX (1) MX2012004420A (pt)
NZ (1) NZ598972A (pt)
PE (1) PE20121437A1 (pt)
TN (1) TN2012000152A1 (pt)
TW (1) TW201124415A (pt)
WO (1) WO2011046851A1 (pt)
ZA (1) ZA201202560B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108069C2 (uk) 2009-03-23 2015-03-25 Гленмарк Фармасьютікалс, С.А. Злиті піримідиндіонові похідні як модулятори trpa1
AU2010227225A1 (en) 2009-03-23 2011-09-15 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as TRPA1 modulators
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
BR112012015612A2 (pt) 2009-12-25 2016-03-15 Mochida Pharm Co Ltd novo derivado de 3-hidróxi-5-arilisotiazol
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
EP2683251B1 (en) 2011-03-11 2021-08-25 Intercontinental Great Brands LLC Method of forming multilayer confectionery
EP2703394A4 (en) 2011-04-27 2014-11-05 Mochida Pharm Co Ltd NEW 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE
CA2834465A1 (en) 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
SI2920165T1 (sl) 2012-11-16 2017-02-28 Bristol-Myers Squibb Company Modulatorji dihidropirazola GPR40
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
AU2014372114A1 (en) * 2013-11-14 2016-06-09 Cadila Healthcare Limited Novel heterocyclic compounds
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
CN111423408A (zh) * 2014-10-17 2020-07-17 现代药品株式会社 代谢性疾病的预防或治疗用复合制剂
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
KR20200108318A (ko) 2018-01-08 2020-09-17 셀론 파르마 에스.에이. Gpr40 작용제로서 3-페닐-4-헥신산 유도체
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316559T3 (es) 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
CN101108825A (zh) * 2003-04-04 2008-01-23 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
EP1682136A4 (en) * 2003-11-04 2009-06-03 Elixir Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND CORRESPONDING USES THEREOF
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
BRPI0818687A2 (pt) 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
EP2224803B1 (en) 2007-11-21 2014-04-02 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
EA201270560A1 (ru) 2012-09-28
PE20121437A1 (es) 2012-10-26
CL2012000921A1 (es) 2012-09-14
TW201124415A (en) 2011-07-16
US8383642B2 (en) 2013-02-26
WO2011046851A1 (en) 2011-04-21
EP2488500A1 (en) 2012-08-22
MA33662B1 (fr) 2012-10-01
ZA201202560B (en) 2013-09-25
IL218344A0 (en) 2012-04-30
JP2013508279A (ja) 2013-03-07
US20110092531A1 (en) 2011-04-21
CO6531458A2 (es) 2012-09-28
AR078522A1 (es) 2011-11-16
DOP2012000105A (es) 2013-01-31
NZ598972A (en) 2013-06-28
AU2010307094A1 (en) 2012-04-19
CA2777775A1 (en) 2011-04-21
MX2012004420A (es) 2012-05-08
ECSP12011799A (es) 2012-07-31
CN102574807A (zh) 2012-07-11
CR20120177A (es) 2012-06-06
KR20120051777A (ko) 2012-05-22
TN2012000152A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
BR112012012903A2 (pt) compostos de espiropiperidina
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
PH12015501678A1 (en) Inhibitors of influenza viruses replication
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
BRPI0507198A (pt) derivados de bisariluréia
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
WO2012083122A8 (en) Inhibitors of influenza viruses replication
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
EA201390198A1 (ru) Гетероциклическое соединение
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BRPI1014802B8 (pt) profármacos de triptolida.
BR112012031634A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio
BR112012024586A2 (pt) compostos de purina
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
BR112013018738A2 (pt) novos derivados de tetrahidroquinolina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.